Jim Wilson Praises iECURE's Milestone in Gene Therapy with ECUR-506 for OTCD
Advancements in Gene Therapy: Jim Wilson Reviews iECURE's Breakthrough
On January 9, 2025, Dr. Jim Wilson, who holds the position of President and CEO at GEMMA Biotherapeutics, alongside being a co-founder of iECURE, expressed his excitement regarding the latest developments shared by iECURE. The company recently announced that the first infant treated with the gene-editing therapy ECUR-506 for Ornithine Transcarbamylase Deficiency (OTCD) showcased a complete clinical response.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.